Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment.

摘要

We read with great interest the article by Jung et al (1) in the January 2010 issue of Critical Care Medicine. In this prospective study of patients with methicil-lin-resistant Staphylococcus aureus (MRSA) pneumonia, they described that in the modified intention-to-treat population clinical cure rates were evaluated on day 14 of treatment, with 53.7% success for the vancomycin and rifampicin combination therapy group (VR group) and 31.0% success for those treated with vancomycin alone (p = .047). They concluded that vancomycin plus rifampicin seemed to be more effective than vancomycin alone in the treatment of nosoco-mial MRSA pneumonia.